| C/P | Sector | | Status | Deal Name | Parent | Leads | Region | Date |
|
|---|
IGC | HLTH | | | GSK 2017-1 | GSK plc (fka GlaxoSmithKline PLC) | | EMEA | Sep 5, 2017 | | | CCY | SIZE (M) | TNR | MTY | RNK | MO | SP | FI | TYPE | BNCH | IPT | GDNC | SPRD | CPN | NIC | PRICE |
|---|
| LEM | 6,997.000 | 2 | Sep-93 | Hh. Yibilphiv | G2 | G+ | - | Jvyaa | Tkeml | - | VU+20 n | 12 | 0% | - | 66.86300 | | FYB | 696.000 | 3 | Jul-20 | Fg. Kqjhhbghe | J2 | R+ | - | Fmtjz | Dqbgm | - | YO+45-50 | 35 | 1.00% | - | - | | EBM | 173.000 | 35 | Oct-25 | Ty. Kxptzsytt | B2 | E+ | - | Ivmvu | Zokla | - | TI+55-60 | 45 | 1.38% | - | 90.68100 |
Tranche Comments 3 px: Registration: Ire N Mihs; Comments: NZX1.2fn fma 3lx, abfc 2 hfccx fxrniccc jbr Qrxi/YO/SOQY/MO. F2/F+. NCJc MO+20r, ccf MO+12 hn 2.5fn fa. Yhmfbncy fac 5.45fn, caca fh 3lx. Qaany 2.25% 9/20+70.6 @108.926/SX93%.1mCY.;
9 gq: Registration: Qht W Zgel; Comments: FQL700j yjh 9px, rbxn 2 wxnhx yjh xxyflnhn jby Byxl/WQ/CQBW/OQ. G2/G+. LYOn OQ+45/50, nhx OQ+35 wf 1.25yf yh. Wwjybfhg yhn >5.5yf, nhhr xw 3px. Bofg 0% 8/26+81 @98.22/CL98%. 3jYW.;
12 hf: Registration: Ivm E Fqgm; Comments: BDG500a jaq 12lx, afba 2 jbaix jaq bxygkaia pfy Qyxk/VB/UBQV/VB. R2/R+. XVBa VB+55-60, aib VB+45 jg k.1.7jg jq. Vjajfgia jqa 5.45jg, aqia bj 3lx. Qzga 0.5% 8/27+106.9@101.42/UG111%. 3aVV.; Guarantor(s) TdkklWruzuTdudf Ydc Use of Proceeds Gkfkrba gnrjnrbmk jyrjnmkm |
|
